Cor Vasa 2014, 56(3):e254-e258 | DOI: 10.1016/j.crvasa.2014.03.001

The WOEST study: Critical considerations and applicability

Andrea Rubbolia, Raffaele De Caterinab,c,*
a Division of Cardiology, Laboratory of Interventional Cardiology, Maggiore Hospital, Bologna, Italy
b Institute of Cardiology and Center of Excellence on Aging, G. d'Annunzio University - Chieti, Italy
c Fondazione G. Monasterio - Pisa, Italy

Triple therapy (TT) with a vitamin K-antagonist (VKA), aspirin, and clopidogrel is currently recommended as the optimal antithrombotic therapy for patients with an indication for oral anticoagulation undergoing percutaneous coronary intervention with stent implantation (PCI-S). While appearing highly effective for preventing the combined incidence of death, myocardial infarction, repeat revascularization, stent thrombosis, and stroke, TT is associated with a high incidence of bleeding. In the recent What is the Optimal antiplatElet and anticoagulant therapy in patients with oral anticoagulation and coronary StenTing (WOEST) study, dual therapy (DT) with warfarin and clopidogrel has been shown to be significantly safer than TT on the occurrence of total bleeding, with no apparent reduction in efficacy, as the combined incidence of death, myocardial infarction, repeat revascularization, stent thrombosis, and stroke was actually also significantly lower in the DT than in the TT arm. Because of the underpowered size of the WOEST study for a reliable evaluation of the efficacy outcomes, especially stent thrombosis, and because of the limited superior safety of DT vs TT for the occurrence of clinically major bleeding, we maintain that the results of the WOEST study should not precipitously lead to the adoption of DT as the antithrombotic regimen of choice for patients with an indication for VKA who are submitted to PCI-S.

Keywords: Antiplatelet therapy; Oral anticoagulation; Percutaneous coronary intervention; Stent; Stent thrombosis; Triple therapy; Vitamin K-antagonists

Received: December 31, 2013; Accepted: March 2, 2014; Published: June 1, 2014  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Rubboli A, De Caterina R. The WOEST study: Critical considerations and applicability. Cor Vasa. 2014;56(3):e254-258. doi: 10.1016/j.crvasa.2014.03.001.
Download citation

References

  1. G.Y. Lip, K. Huber, F. Andreotti, et al., European Society of Cardiology Working Group on Thrombosis, Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary intervention/stenting, Thrombosis and Haemostasis 103 (2010) 13-28. Go to original source... Go to PubMed...
  2. D.P. Faxon, J.W. Eikelboom, P.B. Berger, et al., Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective, Thrombosis and Haemostasis 106 (2011) 572-584. Go to original source... Go to PubMed...
  3. P.G. Steg, K. Huber, F. Andreotti, et al., Bleeding in acute coronary syndromes and percutaneous coronary interventions: position paper by the Working Group on Thrombosis of the European Society of Cardiology, European Heart Journal 32 (2011) 1854-1864. Go to original source... Go to PubMed...
  4. W.J. Dewilde, T. Oirbans, F.W Verheugt, et al., WOEST Study Investigators, Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial, Lancet 381 (2013) 1107-1115. Go to original source... Go to PubMed...
  5. A. Rubboli, A. Sciahbasi, C. Briguori, et al., WARfarin and coronary STENTing registry, In-hospital management and outcome of patients on warfarin undergoing coronary stent implantation: results of the multicenter, prospective WARfarin and coronary STENTing (WAR-STENT) registry, Journal of Invasive Cardiology 25 (2013) 170-176. Go to PubMed...
  6. A. Schlitt, A. Rubboli, G.Y. Lip, et al., for the AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting Study Group), The management of patients with atrial fibrillation undergoing percutaneous coronary intervention with stent implantation: in-hospital-data from the atrial fibrillation undergoing coronary artery stenting study, Catheterization and Cardiovascular Interventions 82 (2013) E864-E870. Go to original source... Go to PubMed...
  7. F. Gao, Y.J. Zhou, Z.J. Wang, et al., Comparison of different antithrombotic regimens for patients with atrial fibrillation undergoing drug-eluting stent implantation, Circulation Journal 74 (2010) 701-708. Go to original source... Go to PubMed...
  8. A. Rubboli, The risk of bleeding of triple therapy of vitamin K-antagonists, aspirin and clopidogrel after coronary stent implantation: facts and questions, Journal of Geriatric Cardiology 8 (2011) 207-214. Go to original source... Go to PubMed...
  9. C.W. Hamm, J.P. Bassand, S. Agewall, et al., ESC Committee for Practice Guidelines, ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC), European Heart Journal 32 (2011) 2999-3054.
  10. F. Qian, T.M. Osler, M.P. Eaton, et al., Variation of blood transfusion in patients undergoing major noncardiac surgery, Annals of Surgery 257 (2013) 266-278. Go to original source... Go to PubMed...
  11. D.R. Holmes jr, D.J. Kereiakes, S. Garg, et al., Stent thrombosis, Journal of the American College of Cardiology 56 (2010) 1357-1365. Go to original source... Go to PubMed...
  12. R. Sørensen, M.L. Hansen, S.Z. Abildstrom, et al., Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data, Lancet 374 (2009) 1967-1974. Go to original source... Go to PubMed...
  13. M.L. Hansen, R. Sørensen, M.T. Clausen, et al., Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation, Archives of Internal Medicine 170 (2010) 1433-1441. Go to original source... Go to PubMed...
  14. F. Sofi, R. Marcucci, A.M. Gori, et al., Clopidogrel non-responsiveness and risk of cardiovascular morbidity. An updated meta-analysis, Thrombosis and Haemostasis 103 (2010) 841-848. Go to original source... Go to PubMed...
  15. A. Rubboli, M. Milandri, C. Castelvetri, B. Cosmi, Meta-analysis of trials comparing oral anticoagulation and aspirin versus dual antiplatelet therapy after coronary stenting. Clues for the management of patients with an indication for long-term anticoagulation undergoing coronary stenting, Cardiology 104 (2005) 101-106. Go to original source... Go to PubMed...
  16. M. Lamberts, G.H. Gislason, J.B. Olesen, et al., Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention, Journal of the American College of Cardiology 62 (2013) 981-989. Go to original source... Go to PubMed...




Cor et Vasa

You are accessing a site intended for medical professionals, not the lay public. The site may also contain information that is intended only for persons authorized to prescribe and dispense medicinal products for human use.

I therefore confirm that I am a healthcare professional under Act 40/1995 Coll. as amended by later regulations and that I have read the definition of a healthcare professional.